Microsite Matches Oncology Sponsors with Canadian Investigators
Scimega Research, an oncology-focused CRO, has launched its new Reverse Feasibility Resource Center
Scimega Research, (www.scimega.com) an oncology-focused CRO, has launched its new Reverse Feasibility Resource Center, that is aimed at matching U.S. oncology sponsors in need of Canadian investigators and their patients.
This microsite will be updated regularly to highlight Canada’s expertise in both early and late phase oncology trials. It currently features important information such as the number of oncology sites, key investigators, and the size of the catchment areas for each of the ten Canadian provinces. Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. This Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for a trial, including lines of treatment, tumor types and targets.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
